Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

Cited by (176)

Items 101–176 of 176

1. Targeted protein degradation: bridging chemical biology and clinical translation
   Yubo Zhang, Jun-wei Fu, Yue Liu, R Y Wu, Yanting Liang, Wei Zhang, Tao Yuan, Hao Zhu, Qiao-Jun He, Bo Yang · 2026 · Acta Pharmacologica Sinica
2. BTK degraders tackle drug resistance
   M. Teresa Villanueva · 2024 · Nature Reviews Drug Discovery
3. Emerging pharmacology of targeted protein degraders
   Samir H. Barghout, Mohamed A. Eldeeb · 2025 · Journal of Pharmacology and Experimental Therapeutics
4. Degraders of cell cycle- and antiapoptosis-related proteins
   Yingqiong Zhang, Rong Dong, Bo Zhang · 2025 · Elsevier eBooks
5. From C481 Resistance Evasion to Platelet Preservation: Rilzabrutinib Redefines ITP Targeted Therapy
   Long Liu, Yang Xiao, Yanyan Jia, Ziyi Shao, Jingfei Shi, Chao Cui · 2025 · Drug Design Development and Therapy
6. When Targeted Therapy Falls Short: Unraveling Resistance Mechanisms in Chronic Lymphocytic Leukemia
   Samon Benrashid, Jennifer Ann Woyach · 2026 · Current Hematologic Malignancy Reports
7. Attacking the “undruggable” target: The rise and evolution of targeted protein degradation technologies
   Qihang Huang, Qianwen Mu, NiNa Liu, Gang Liu, Chao Liu · 2026 · Advanced Interventional Materials
8. Therapy-driven clonal dynamics in chronic lymphocytic leukemia
   Larry Mansouri, Thomas Chatzikonstantinou, Lydia Scarfò, Richard Rosenquist · 2026 · Seminars in Cancer Biology
9. Targeted proteoform degradation for precision drug design, delivery, and therapy
   Chenyu Cui, Haitao Zhang, Xinmiao Wang, Ning Li, Xianquan Zhan · 2026 · Drug Delivery
10. Low-dose EGFR inhibition unlocks ferroptosis susceptibility to sensitize chemotherapy in EGFR-high triple-negative breast cancer
    Xiaoxi Li, Ling Liu, Lingli Luo, Minyao Deng, Yong Jiang, Weijun Ren, Hui Qian · 2026 · Journal of Biological Chemistry
11. A set of equations for random degradation quantifies the role of polymer coatings in mitigating the acquired heterogeneity of corrodible metals for biodegradable stents
    Xin Li, Wenjie Wu, Wanqian Zhang, Hong Qiu, Xun Ma, Hongjie Zhang, Yongli Qi, Haiping Qi, Ye Fu, Lei Song et al. · 2026 · Science China Materials
12. Design and delivery of targeting chimeras therapeutics in managing central nervous system disorders
    Shuo Liu, Wei Xu, Mengxi Wang, Zhen Mao, Jianping Zhou, Xiaochen Gu, Guochen Han, Yang Ding · 2026 · Targetome
13. Mechanisms of resistance to BTK inhibitors in B cell malignancies and emerging targeted strategies
    Qinyu Ni, Lixin Rui · 2026 · Molecular Therapy Oncology
14. Targeted protein degradation dismantles undruggable targets to reverse immune evasion and therapy resistance in cancer
    张富荣, Qianheng Wang, Mingxuan Li, Tingting Wang, Ping Lei, Tao Huang, Zhenghao Wu · 2026 · Frontiers in Immunology
15. Proteolysis targeting chimeras for drug discovery from mechanistic basis to clinical translation
    Sandip G. Badadhe, Vikas B Gawali, Mahesh D Bhalsing, Chandraprabhu Jangme · 2026 · Discover Chemistry.
16. Stimulated protein degradation to promote mitochondrial function and neuronal survival
    Srividya Chandrasekhar, Rachael A. McMinimy, Andrew G. Manford, Eddie Wehri, Christine L. Gee, Caitlyn Miller, Baris Bingol, John Kuriyan, Julia Schaletzky, Michael Rapé · 2026 · Science
17. Engineering ERα degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases
    Anna Shemorry, Willem den Besten, Melinda M. Mulvihill, Curt J. Essenburg, Nicole Blaquière, Tracy Kleinheinz, Elisia Villemure, Frank Peale, Gauri S. Deshmukh, Danilo Maddalo et al. · 2025 · Cell chemical biology
18. Big cells, bigger BTK resistance in mantle cell lymphoma
    Justin Taylor · 2025 · Blood
19. Dual targeting of BTK and BCL2 enhances apoptosis in marginal zone lymphoma models: preclinical activity of BGB-16673 and sonrotoclax
    Alberto J. Arribas, Elisa Civanelli, Camilla Scalise, Luciano Cascione, Andrea Rinaldi, Davide Rossi, Emanuele Zucca, Laura Carosella, Stefano Raniolo, Vittorio Limongelli et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
20. Shifting clones: CLL evolution under pirtobrutinib treatment
    Billy Michael Chelliah Jebaraj, Stephan Stilgenbauer · 2026 · Blood
21. Bexobrutideg: A Selective, Catalytic Degrader of Bruton’s Tyrosine Kinase Overcomes Inhibitor Resistance and Suppresses Autoantibody-Mediated Disease
    Mark Noviski, P Auger, Danielle Bautista, Nivetha Brathaban, Brandon J. Bravo, Robert Cass, Ganesh Cherala, Thomas C. Fung, Stefan Gajewski, Dhwani Haria et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
22. Degradation trumps mutations in cancer
    Richard Eric Davis, Jason R. Westin · 2024 · Science
23. Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial
    Barbara F. Eichhorst, Elisa ten Hacken · 2024 · Seminars in Hematology
24. Identification of Suitable Target/E3 Ligase Pairs for PROTAC Development using a Rapamycin-induced Proximity Assay (RiPA)
    Bikash Adhikari, Katharina Schneider, Mathias Diebold, Christoph Sotriffer, Elmar Wolf · 2024 · eLife
25. eLife Assessment: Identification of Suitable Target/E3 Ligase Pairs for PROTAC Development using a Rapamycin-induced Proximity Assay (RiPA)
    Agnieszka Chacińska · 2024 · eLife
26. Reviewer #1 (Public Review): Identification of Suitable Target/E3 Ligase Pairs for PROTAC Development using a Rapamycin-induced Proximity Assay (RiPA)
    Bikash Adhikari, Katharina Schneider, Mathias Diebold · 2024 · eLife
27. Reviewer #2 (Public Review): Identification of Suitable Target/E3 Ligase Pairs for PROTAC Development using a Rapamycin-induced Proximity Assay (RiPA)
    Bikash Adhikari, Katharina Schneider, Mathias Diebold · 2024 · eLife
28. Repurposing Tolfenamic Acid to Anchor the Uncharacterized Pocket of the PUB Domain for Proteolysis of the Atypical E3 Ligase HOIP
    Fumei Zhong, Yu Zhou, Mingqing Liu, Lei Wang, Fudong Li, Jiahai Zhang, Zhi‐Yong Han, Yunyu Shi, Jia Gao, Ke Ruan · 2024 · ACS Chemical Biology
29. Identification of Suitable Target/E3 Ligase Pairs for PROTAC Development using a Rapamycin-induced Proximity Assay (RiPA)
    Bikash Adhikari, Katharina Schneider, Mathias Diebold, Christoph Sotriffer, Elmar Wolf · 2024 · eLife
30. Consensus guidelines for the management of treatment-naïve chronic lymphocytic leukaemia in Singapore (2024)
    Yeow Tee Goh, Yvonne Loh, Esther Hian Li Chan, Yuh Shan Lee, Venkata Sreekanth Sampath, Daryl Chen Lung Tan, Shin Yeu Ong, Chandramouli Nagarajan · 2025 · Annals of the Academy of Medicine Singapore
31. Case report: A panorama gene profile of ovarian cancer metastasized to axillary lymph node
    Yu Xia, Yu‐Tung Huang, Zheng Liu, Siyuan Song, Yi Wang, Jing Luo · 2025 · Frontiers in Immunology
32. Application of DELs for E3 Ligase Ligand Discovery and Targeted Protein Degradation
    Marie L. Malone, Nicholas A. Sanchez, Stacy L. Hu, Christopher B. Phelps · 2025 · Royal Society of Chemistry eBooks
33. The next frontier in drug discovery: Unveiling the pharmacological potential of proximity inducers
    Natalie Holmberg‐Douglas, Katherine N. Keenan, Felix González-López de Turiso, Eugene P. Chekler, Veerabahu Shanmugasundaram, Jennifer R. Riggs, Christoph W. Zapf · 2025 · Elsevier eBooks
34. Research Progress in Hematological Malignancies: A Molecular Genetics Perspective
    Rina Kansal · 2025 · Genes
35. Advancing BTK Inhibition: Non‑Covalent Bruton Tyrosine Kinase Inhibitors and Their Emerging Role in Canadian Practice
    Jonathan Isenberg, Alina S. Gerrie · 2025 · Canadian Hematology Today
36. EXABS-210-CLL: New Targets and Drugs on the Horizon in Chronic Lymphocytic Leukemia
    Meghan C. Thompson · 2025 · Clinical Lymphoma Myeloma & Leukemia
37. Discovery and Development of a Potent LIMK2 Isoform-Specific Degrader
    Kamal Rayees Abdul Azeez, Hayuningbudi Saraswati, Thorsten Mosler, Thomas Hanke, Hung xuan Ho, Noah Neder, Saran Aswathaman Sivashanmugam, Marcel Heinz, Martin P. Schwalm, Giulio Giuliani et al. · 2026 · ACS Chemical Biology
38. Development of a Partial Proteolysis Targeting Chimera Library Based on Achiral Cereblon E3 Ligase Ligands and its Application for Bruton's Tyrosine Kinase Degraders
    Chelsi M. Almodóvar‐Rivera, Ira Tandon, Ramesh Mudududdla, Paulina N. Esguerra, Kevin Lucio‐Acero, Weiping Tang · 2025 · ChemMedChem
39. NX-5948: a Bruton’s tyrosine kinase degrader in Ph. Ia/Ib for patients with advanced B-cell malignancies
    Chunhua Ma · 2025 · Elsevier eBooks
40. Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center
    Kevin Lin, Lynn Y Huynh, Xiaoqin Yang, Enrico Zanardo, Daria Liborski, Mikaela M. McDonough, Mohammed Z.H. Farooqui, Enrico De Nigris, Shravanthi R. Gandra, Mei Sheng Duh et al. · 2025 · Advances in Hematology
41. REL overexpression and sustained NF-κB signaling associated with 2p gain induce resistance to BTK inhibitors in Chronic Lymphocytic Leukemia
    Léa Dehgane, Eliane Mallet, Constance Brasseur, Daphné Krzisch, Wail Zeitouni, Casilda Hitier, Marianne Ayoub, Kenza Dubois, Claudia Pérez Carretero, Damien Roos‐Weil et al. · 2025 · Leukemia
42. Overcoming BTK Inhibitor Resistance in Chronic Lymphocytic Leukemia by Targeting PKCβ
    Billy Michael Chelliah Jebaraj, Stephan Stilgenbauer · 2025 · Blood Cancer Discovery
43. Defining the acute BTK-loss transcriptional program in CLL using a BTK degrader
    Mingma G. Sherpa, Sutapa Sinha, Weiguo Han, Heather C. Darby, Sameer Ashok Parikh, Neil E. Kay, Zhiquan Wang · 2026 · Leukemia
44. Precision targeting of BTK in chronic lymphocytic leukemia: computational insights into structural dynamics and the influence of mutations on BTK inhibitors through QM and MM studies
    S Hussain, Manisha Agarwal, Sanchaita Rajkhowa, Abhichandan Das, Subrata Sinha, Magdi E. A. Zaki · 2026 · Journal of Biomolecular Structure and Dynamics
45. Kinase inhibition for noncatalytic function
    Zi Wang, Kaijie Zhou, Ke Ding · 2026 · Elsevier eBooks
46. Harnessing Targeted Protein Degradation for Developing Brain Cancer Therapy
    Osaid Muhammad, Sophie White, Carina Jungha Dumo, Thomas I‐H. Park, Peter J. Choi, Jiney Jose · 2026 · Bioconjugate Chemistry
47. Targeted protein degradation in the digital era: Computational challenges and opportunities for PROTACs
    Aishani Tewari, Aiswarya B. Pawar, Sudip Roy · 2026 · In Silico Research in Biomedicine
48. Defining the BTK-dependent chromatin-informed gene regulatory network in chronic lymphocytic leukemia
    Zhiquan Wang, Weiguo Han, Qianqian Guo, Heather M. Darby, Sutapa Sinha, Chuanhe Yu, Sameer Parikh, Neil E. Kay · 2026 · Research Square
49. PLCG2 exon-skipped variants: insights into their potential role in chronic lymphocytic leukemia
    Jialei Qi, Wen Li, Rashmi Priyadharshini Dheenadayalan, Deyan Yordanov Yosifov, Carine Cristiane Drewes, Martin Wist, Marcel Wieczorek, Vera Schmid, Elias Hobeika, Xiang Gao et al. · 2026 · Blood Advances
50. A PROTAC-inspired bifunctional small molecule recruits CDK6 to target EYA2 degradation and suppress breast tumor growth
    Yanhui Zhang, Chenchen Kan, Jiaxin Ai, Rui Zhou, Qun Zhao, Jiahui Gao, Yu Wang, Zhaofeng Wu, Xiaoyu Qin, Junting Ma et al. · 2026 · European Journal of Medicinal Chemistry
51. Three generations, one target: BTK inhibitors in lymphoma
    Anja Schmitt, Stephan Hailfinger · 2026 · Blood Advances
52. BTK Degraders in Lymphoid Malignancies: New Modality, New Resistance Rules?
    Alberto J. Arribas, Carlo Visco, Francesco Bertoni · 2026 · Blood Cancer Discovery
53. Covalent Bruton’s tyrosine kinase inhibitor HZ-A-018 in patients with relapsed or refractory B cell malignancies: A multicenter phase I study
    Guolan Wu, W. Juying, Haiyan Yang, Lianlian Fan, Songxia Yu, Jingjing Zhang, Meihua Lin, H J Zhou, Nana Xu, Miao Hu et al. · 2026 · iScience
54. Targeting Bruton’s Tyrosine Kinase in CLL: Selectivity, Resistance Mechanisms, and Emerging Therapeutic Strategies
    Eduardo Bravo, Claudia C. Pastrana, Erica N. Lamkin, Katarzyna Ciurko, Justin Taylor · 2026 · Cells
55. Beyond the ATP-binding pocket: emerging strategies in kinase targeting from allosteric inhibition to targeted protein degradation
    Mei Zhou, Linshan Li, Xiaojuan Tang, Yazhu Zhao, Wei Zhang · 2026 · Future Medicinal Chemistry
56. Discovery of Highly Potent and Selective, Orally Bioavailable BTK-Targeting PROTACs Featuring Novel CRBN-Binding Warheads
    Alexey B. Mantsyzov, Pei Zhao, Chris Gerrit Kruse, Rostislav A. Petrov, Fubao Huang, Jiaojiao Yu, Xin Cai, Xiao Ding, Vladimir Aladinskiy, Alex Aliper et al. · 2026 · Journal of Medicinal Chemistry
57. Integrative Proteomics and Ubiquitomics Reveal on-Targets and off-Targets of PROTAC dBET1
    Hongtao Wen, Hui Liu, Jinfang Liu, Bendong Yang, Jiaxing Dai, Lei Chang, Yanchang Li, Yao Zhang, Liyan Yu, Ping Xu · 2026 · Analytical Chemistry
58. Sequencing asymmetry: the case for caution before first-line pirtobrutinib in chronic lymphocytic leukemia
    Boyi Chen, Shenxian Qian · 2026 · Annals of Hematology
59. IL-16 drives a novel pathway of BTK inhibitor resistance
    Dimitar G. Efremov · 2026 · Blood
60. From prediction to performance: In silico-supported formulation of amorphous solid dispersions for PROTAC NX-2127
    Alicia Stakemeier, Lukas Mild, Johannes Sievers, Jitka Kalasová, Kristina E. Steffens, Martin Kuentz, Christian Steinebach, Karl G. Wagner · 2026 · International Journal of Pharmaceutics X
61. Current and new approaches to the treatment landscape for adults with Waldenström macroglobulinemia
    Camille Vanessa Edwards, Jorge Julio Castillo, Tarek H. Mouhieddine, Shayna Sarosiek · 2026 · Expert Opinion on Pharmacotherapy
62. From discovery to clinic: Medicinal chemistry strategies for PROTAC linker optimization
    Hongjin Yang, Mingxiao Gu, Zekun Li, Qidong You, Lei Wang · 2026 · European Journal of Medicinal Chemistry
63. Targeted degradation of protein in hematologic malignancies: mechanisms, therapeutic strategies, and clinical prospects
    Sana Nafees, Glowi A. Alasiri, Mohammad Suhail Akhter, Nemat Ali · 2026 · Cancer Gene Therapy
64. Fitness criteria for PROTACs as chemical probes: principles and applications
    Manon Sturbaut, Alessio Ciulli · 2026 · Essays in Biochemistry
65. Advances in molecular pathobiology of PCNSL – towards clinical implementation of novel diagnostics and therapeutics
    Yi Chye Law, Jason Yongsheng Chan · 2026 · Biomarker Research
66. Bruton's Tyrosine Kinase Inhibitors: Mechanisms, Efficacy, Toxicities and Applications for the Treatment of Human Diseases
    Miao Sun, Dengju LI, Jia Wei · 2026 · MedComm
67. Beyond the binding site: PROTAC-mediated protein degradation assists the therapeutic paradigm of hematological malignancies
    Mahsa Fatahichegeni, Mohammad Amin Ansarian, Yuqi Wang, Tongxin Zhang, Ruimin Liu, Juan Ren, Xiaoning Wang · 2026 · Leukemia Research
68. Resistance to covalent Bruton's tyrosine kinase inhibitors in diffuse large B‑cell lymphoma: Molecular mechanisms and therapeutic implications (Review)
    Chuanyang Lu, Tingting Yang, Wenxin Zhang, lulu Wei, Qiuni Chen, Yuye Shi, Chunling Wang, Yu Liang · 2026 · International Journal of Oncology
69. Rigorous Absolute Binding Free Energy Calculations Elucidate Mutation–Driven Resistance Mechanisms of Non–Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitors
    Justice Josiah Mallen, Shilpa Sharma, Md. Nazmul Hasan, Arjun Saha · 2026 · ACS Omega
70. Emerging drug profile: bexobrutideg
    T. N. Huynh, Sonia Rodriguez‐Rodriguez, Alexey Valeryevich Danilov · 2026 · Leukemia & lymphoma/Leukemia and lymphoma
71. Disease-guided targeted protein degradation and clearance: matching strategies to pathological protein states
    Tianyu Wang, Chenbo Ji, Tianyu Zhao · 2026 · Frontiers in Medicine
72. BindingDB Entry 50023383: Discovery and Functional Characterization of a Potent, Selective, and Metabolically Stable PROTAC of the Protein Kinases DYRK1A and DYRK1B.
    BindingDB · 2026 · UC San Diego
73. BindingDB Entry 50022929: Discovery of an Efficacious RET PROTAC Degrader with Enhanced Antiproliferative Activity against Resistant Cancer Cells Harboring RET Solvent-Front Mutations.
    BindingDB · 2026 · UC San Diego
74. BindingDB Entry 50019770: Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies.
    BindingDB · 2024 · UC San Diego
75. A Value-Based Framework for CLL Care: Results of a Scoping Review
    Stefano Molica, David John Allsup · 2026 · Cancers
76. The Future of Targeted Degradation: Outlook and Unanswered Questions
    Tingting Xiong, Chunrong Yang, Jinghong Li · 2026 · Handbook of experimental pharmacology